Patents Examined by My-Chau T Tran
  • Methods of treating cancer with atovaquone-related compounds
    Patent number: 10130590
    Abstract: Described herein are, inter alia, methods for decreasing the growth of a cancer cell, the method comprising delivering to a target cancer cell a growth-inhibitory amount of an atovaquone-related compound, wherein, prior to the delivery, an increased level of activation of the mTOR pathway in the cancer compared to a control level of activation of the mTOR pathway has been found. Also provided are methods for determining the susceptibility of cancer to treatment with an atovaquone-related compound and for assessing the success of therapy with such a compound.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: November 20, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Frank, Michael Xiang
  • Anti-cancer agent
    Patent number: 10111892
    Abstract: The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R1 and R2 represent a linear or branched alkyl group, and R1 has a higher priority than R2 as ranked according to RS notation. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X? represents an anion.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: October 30, 2018
    Assignee: Nippon Chemical Industrial Co., Ltd.
    Inventors: Nobuhiko Oohara, Kazuhiro Nakatsui
  • Triheptanoin for the treatment of glucose transport 1 deficiency
    Patent number: 10111848
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 30, 2018
    Assignees: National Institute of Health and Medical Research, Baylor Research Institute
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Transient protection of normal cells during chemotherapy
    Patent number: 10085992
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 2, 2018
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • HSPC-sparing treatments for RB-positive abnormal cellular proliferation
    Patent number: 10076523
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: September 18, 2018
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Medicament for suppressing malignant tumor metastasis
    Patent number: 10071099
    Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 11, 2018
    Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Kenji Kangawa, Hiroshi Hosoda, Takashi Nojiri
  • Agonists that enhanced binding of integrin-expressing cells to integrin receptors
    Patent number: 10071980
    Abstract: A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 11, 2018
    Assignee: TEXAS HEART INSTITUTE
    Inventors: Ronald J. Biediger, Robert V. Market
  • Methods of treatment of diseases
    Patent number: 10058562
    Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The method comprises administering an effective amount of a danazol compound to the animal accounting for the body fat content of the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 28, 2018
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Compounds for the treatment of mTOR pathway related diseases
    Patent number: 10053422
    Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Pitney Pharmaceuticals Pty Limited
    Inventors: Mohammad Hossein Pourgholami, David L. Morris, Roger Aston
  • Co-crystals and pharmaceutical compositions comprising the same
    Patent number: 10039761
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Antimicrobial compositions
    Patent number: 10028924
    Abstract: Antimicrobial compositions and related methods are disclosed. The antimicrobial compositions include glycolic acid, an anionic surfactant, and at least one additional surfactant selected from anionic and nonionic surfactants.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: July 24, 2018
    Assignee: DeLaval Holding AB
    Inventors: Sarah Leibowitz, N. Camelia Traistaru
  • Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery
    Patent number: 10029014
    Abstract: The present disclosure relates to a dendrimer-based conjugate of the formula Vm-D-C-D?-(T-F)n, which is useful for tumor targeting drug delivery. The use of asymmetric dendrimers allow for specific targeting as well as synthetic reproducibility.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: July 24, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Tao Wang, Yu-Han Teng
  • Compounds, compositions, and methods for the treatment of cancers
    Patent number: 10011622
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 3, 2018
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Mark T. Bilodeau, Benoît Moreau, Adam H. Brockman
  • Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
    Patent number: 10010532
    Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 3, 2018
    Assignee: The University of Utah Research Foundation
    Inventor: Tianxin Yang
  • Mineral amino-acid complexes of active agents
    Patent number: 9999626
    Abstract: The present invention provides compounds of Formula I and related compositions and methods.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 19, 2018
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias
  • ALK and NTRK1 fusion molecules and uses thereof
    Patent number: 10000814
    Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: June 19, 2018
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
  • Combination therapies of EGFR inhibitors
    Patent number: 9993551
    Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 12, 2018
    Assignee: Novartis AG
    Inventors: David Lebwohl, Malte Peters
  • Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
    Patent number: 9980976
    Abstract: Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: May 29, 2018
    Assignee: Northwestern University
    Inventors: Irina Budunova, Gleb Baida, Joel Dudley
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9980963
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 29, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Shuichan Xu, Antonia Lopez-Girona, Toshiya Tsuji, Kristen Mae Hege
  • Intravenous administration of tramadol
    Patent number: 9980900
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 29, 2018
    Assignee: Revogenex Ireland LTD
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping